Insys Therapeutics has been granted FDA orphan drug designation for its cannabidiol drug to treat glioblastoma multiforme
Glioblastoma Multiforme (GBM), the most common and aggressive form of brain cancer, is usually incurable and leads to death in most patients. However, hope may be on the horizon with a new cannabis based drug that has received FDA Orphan Drug Designation this week.
Insys Therapeutics has received FDA orphan drug designation for their pharmaceutical cannabidiol drug for the treatment of GBM. In addition to receiving the investigational designation, the company has also entered into a licensing agreement with California Pacific Medical Center Research Institute to license them with patents right in relation to the use of cannabinoid based drugs to treat GBM.
As part of the agreement, the pharmaceutical company is working with Dr.Sean McAllister at the Research Institute in a pre-clinical study to see if cannabidiols have the ability to sensitise GBM patients to chemotherapy, so that the chemotherapy is more effective.
Insys has already had experience with cannabis based drugs. The company manufactures dronabinol and cannabidiol for pharmaceutical use at its plant in Round Rock, Texas. Insys has also received orphan drug designation for cannabidiol for other indications, including forms of epilepsy such as Dravet syndrome.
If clinical trials for the drug prove to be successful, there may very well be a a very bright future for cannabis based drugs.
Read more about it here: Insys Therapeutics Gets FDA Orphan Drug Designation For Pharma Cannabidiol